

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Ipilimumab

Initial application — stage III or IV resectable melanoma

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

☐ The individual is currently on treatment with ipilimumab for neoadjuvant treatment of resectable stage IIIB, IIIC, IIID or IV melanoma and met all remaining criteria prior to commencing treatment

or

- ☐ The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note)
- and
- ☐ The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma
- and
- ☐ The individual has ECOG performance score 0-2
- and
- ☐ Treatment must be prior to complete surgical resection
- and
- ☐ Neoadjuvant ipilimumab must be administered in combination with nivolumab
- and
- ☐ Ipilimumab to be administered for maximum of two cycles prior to surgical resection

Note:

- Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition.
- Disease must be completely resectable and amenable to curative intent surgery, including stage IV disease.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Ipilimumab - continued

Initial application — renal cell carcinoma

Applications from any relevant practitioner. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ The patient is currently on treatment with ipilimumab and met all remaining criteria prior to commencing treatment
- or
- ☐ The patient has metastatic renal cell carcinoma

and ☐ The patient is treatment naive

and ☐ The patient has ECOG performance status 0-2

and ☐ The disease is predominantly of clear cell histology

☐ The patient has sarcomatoid histology

or ☐ Haemoglobin levels less than the lower limit of normal

or ☐ Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L)

or ☐ Neutrophils greater than the upper limit of normal

or ☐ Platelets greater than the upper limit of normal

or ☐ Interval of less than 1 year from original diagnosis to the start of systemic therapy

or ☐ Karnofsky performance score of less than or equal to 70

and ☐ Ipilimumab is to be used at a maximum dose of 1 mg/kg for up to four cycles in combination with nivolumab.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz